Plasma CEA levels on one or more occasions in 39 patients Plasma CEA (ng/ml) No with Crohn's disease, but the numbers in this group were very small. In no case was a figure of 50 ng/ml exceeded, the level pathognomonic of malignancy (A M Neville 1972, personal communication). In patients with ulcerative colitis, the results were analysed on the basis of length of clinical history, extent of large-bowel involvement in the disease process, and the state of activity of the disease. Mean plasma CEA was higher in patients with a long history, patients with panproctocolitis and patients with active disease, than in patients with a short history, less extensive bowel involvement, or whose disease was in remission. In no case, however, were these differences statistically significant. The numbers ofestimations in patients with Crohn's disease were considered to be too small for detailed analysis.
Malignant Disease
One patient developed, and subsequently died from, a carcinoma of the large bowel. He presented in 1962, at the age of 53, with symptoms of intestinal obstruction. Barium enema showed a stenotic lesion in the ascending colon and a right hemicolectomy was performed. Histological examination of the resected specimen showed typical ileocecal Crohn's disease. He was symptom free until August 1971, when he suffered a relapse. This failed to respond to medical treatment and he eventually came to surgery, when an inoperable carcinoma was discovered at the ileocolic anastomosis. Plasma CEA shortly after surgery was 14.0 ng/ml, only slightly elevated. He died a few months later and post-mortem examination confirmed the presence of a large bowel adenocarcinoma with hepatic metastases.
Premalignant Disease
Serial rectal biopsies were performed on all patients. Two patients showed the premalignant changes first described by Morson & Pang (1967) . Both had ulcerative colitis affecting the left colon and rectum. One, a woman of 35, gave a five-year history, the other, a 72-year-old man, gave a comparatively short history of only eighteen months. The plasma CEA levels in both these patients were consistently in the normal range (<12.5 ng/ml).
Conclusion
In this small series we have confirmed the findings of Lo Gerfo and his colleagues, and have found plasma CEA in the range 12.5-50 ng/ml in about one-third of our patients with ulcerative colitis. Similarly, half the results in patients with Crohn's disease, including the only patient to develop a colonic carcinoma, were in the same range. It has proved impossible to establish a definite relationship between plasma CEA and length of history or extent or activity of the disease. It is thus difficult to avoid the conclusion that we are dealing with a completely nonspecific effect.
Similarly, the patients with premalignant mucosal changes did not have raised plasma CEA. Since patients showing such histological appearances are thought almost inevitably to develop frank carcinoma after a variable period, this was a disppointing finding. Measurement of plasma CEA would have been a relatively simple and useful adjunct to rectal biopsy and other conventional clinical and radiological methods in following up patients of this type who have not proceeded to colectomy. Dr 
Immunodiagnosis and Gastrointestinal Cancer
In recent years, 'phase-specific' principles (fcetal antigens) have been recognized with increasing frequency in association with human tumours and particular attention has been paid to their possible role in the diagnosis and treatment of neoplasms.
Of the several principles found to date in association with human gastrointestinal tumours, the most promising, as investigative adjuncts, seems to be the carcinoembryonic antigen (CEA) described initially by Gold & Freedman (1965) . It is a glycoprotein formed by the embryonic liver, pancreas and gastrointestinal tract during the first two trimesters ofpregnancy. Its measurement by radioimmunoassay (Thomson et al. 1969 , Lo Gerfo et al. 1971 , Egan et al. 1972 has recently shown it to be present also in minute amounts in the gastrointestinal tract and plasma of normal adults. Thus it is not truly tumour-specific. We have measured CEA using the radioimmunoassay of Egan et al. (1972) on account of its readier routine clinical applicability. Table 1 summarizes some of our results which are similar to those reported by other workers using different assay procedures (Moore et al. 1971 , Lo Gerfo et al. 1971 , Zamchek et al. 1972 . Approximately 70% of all gastrointestinal tumours yield above normal (> 12.5 ng/ml) values. However, 33 % of inflammatory conditions, in particular ulcerative colitis, Crohn's disease and peptic ulceration, can give false positive results. None the less, only malignant tumours result in plasma levels in excess of 40 ng/ml (Table 1) . Patients with other malignant tumours including those of mammary, bronchial, genitourinary and lymphoreticular origin, can also have elevated plasma CEA levels.
The incidence of positive results increases with tumour spread and this is illustrated by analysis of the data from colonic and rectal carcinomas (Table 2) ; only 45 % of early localized tumours are positive.
Successful and complete removal of tumours is associated most often with a decline of elevated values to normal within two to seven days postoperatively. This fall may be delayed for up to three to four weeks; occasionally, plasma CEA levels may rise in the immediate postoperative phase before declining. Recurrence or incomplete removal of tumours is generally associated with return or maintenance of raised plasma CEA levels respectively. Hence, CEA as measured by present methods, is not tumour specific and a negative result does not exclude the presence of a tumour. However, it seems to be a clinically useful test in association with other investigative parameters to assess the adequacy of surgery and the development of distance recurrences. Certainly a negative result excludes the presence of widespread metastatic disease.
